Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zelenetz, 2014, Non-Hodgkin's lymphomas, version 4.2014, J Natl Compr Canc Netw, 12, 1282, 10.6004/jnccn.2014.0125
Alberta Provincial Hematology Tumour Team. Clinical practice guideline LYHE-002: Lymphoma. Edmonton, Alberta: Alberta Health Services, Cancer Care. September 2012. http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-lyhe002-lymphoma.pdf. Accessed October 21, 2014.
Duncavage E, Advani RH, Agosti S, et al . Template for reporting results of biomarker testing from patients with diffuse large b-cell lymphoma, not otherwise specified (NOS). Northfield, IL: College of American Pathologists. 2014. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-diffuse-large-b-cell-lymphoma-biomarker-14.pdf. Accessed June 30, 2015.
Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2008;194–195. World Health Organization Classification of Tumours; vol 2.
Frei, 2013, Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma, J Clin Pathol, 66, 956, 10.1136/jclinpath-2013-201619
Nie, 2013, Thymidine phosphorylase expression in B-cell lymphomas and its significance: a new prognostic marker?, Anal Quant Cytol Histol, 35, 301
Lilja, 2013, Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma, Histopathology, 63, 438, 10.1111/his.12162
Nakayama, 2014, TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified, Am J Surg Pathol, 38, 228, 10.1097/PAS.0000000000000094
Koh, 2013, Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP, Cancer Sci, 104, 1245, 10.1111/cas.12215
Bedewy, 2013, Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma, Ann Hematol, 92, 1359, 10.1007/s00277-013-1775-4
Choi, 2013, MYD88 expression and L265P mutation in diffuse large B-cell lymphoma, Hum Pathol, 44, 1375, 10.1016/j.humpath.2012.10.026
Wenzel, 2013, MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma, Leukemia, 27, 1381, 10.1038/leu.2012.367
Tinguely, 2014, IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1), Leuk Lymphoma, 55, 136, 10.3109/10428194.2013.793324
Lv, 2013, Overexpression of IL-9 receptor in diffuse large B-cell lymphoma, Int J Clin Exp Pathol, 6, 911
Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855
Morin, 2011, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, 476, 298, 10.1038/nature10351
Cui, 2014, Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma, J Transl Med, 12, 10, 10.1186/1479-5876-12-10
Montes-Moreno, 2012, EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation, Mod Pathol, 25, 968, 10.1038/modpathol.2012.52
Stein, 2008, Diffuse large B cell lymphoma, not otherwise specified, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 233
Miller, 1994, Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial, Blood, 83, 1460, 10.1182/blood.V83.6.1460.1460
Bryant, 2006, Ki-67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders, Histopathology, 48, 505, 10.1111/j.1365-2559.2006.02378.x
Mationg-Kalaw, 2012, Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?, Histopathology, 61, 1214, 10.1111/j.1365-2559.2012.04351.x
Iqbal, 2011, BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab, Clin Cancer Res, 17, 7785, 10.1158/1078-0432.CCR-11-0267
Johnson, 2012, Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, 30, 3452, 10.1200/JCO.2011.41.0985
Hu, 2013, MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, Blood, 121, 4021, 10.1182/blood-2012-10-460063
Seegmiller, 2010, Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas, Mod Pathol, 23, 909, 10.1038/modpathol.2010.76
Mossafa, 2006, Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis, Leuk Lymphoma, 47, 1885, 10.1080/10428190600687547
Lynnhtun, 2014, Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis, Pathology, 46, 211, 10.1097/PAT.0000000000000076
Tapia, 2011, Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas, Histopathology, 59, 672, 10.1111/j.1365-2559.2011.03978.x
Green, 2012, High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma, Am J Surg Pathol, 36, 612, 10.1097/PAS.0b013e318244e2ba
Kluk, 2012, Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas, PLoS One, 7, 10.1371/journal.pone.0033813
Johnson, 2009, Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival, Blood, 114, 2273, 10.1182/blood-2009-03-212191
Ok, 2014, Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program, Cancer, 120, 1818, 10.1002/cncr.28664
Vela-Chávez, 2011, Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus, Leuk Lymphoma, 52, 458, 10.3109/10428194.2010.540361
Hu, 2013, CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, Blood, 121, 2715, 10.1182/blood-2012-10-461848
Campuzano-Zuluaga, 2013, Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases, Leuk Lymphoma, 54, 2405, 10.3109/10428194.2013.778407
Armitage, 2012, My treatment approach to patients with diffuse large B-cell lymphoma, Mayo Clin Proc, 87, 161, 10.1016/j.mayocp.2011.11.007
Ott, 2010, Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL, Blood, 116, 4916, 10.1182/blood-2010-03-276766
Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501
Lenz, 2008, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proc Natl Acad Sci U S A, 105, 13520, 10.1073/pnas.0804295105
Rosenwald, 2002, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, N Engl J Med, 346, 1937, 10.1056/NEJMoa012914
Shipp, 2002, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning, Nat Med, 8, 68, 10.1038/nm0102-68
Hwang, 2014, High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large b-cell lymphoma, not otherwise specified, Am J Surg Pathol, 38, 1046, 10.1097/PAS.0000000000000211
Choi, 2009, A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy, Clin Cancer Res, 15, 5494, 10.1158/1078-0432.CCR-09-0113
Vaidya, 2014, Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era [published online ahead of print March 13, 2014], Ann Oncol, 25, 2124, 10.1093/annonc/mdu109
Hans, 2004, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, 103, 275, 10.1182/blood-2003-05-1545
Muris, 2006, Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma, J Pathol, 208, 714, 10.1002/path.1924
Natkunam, 2008, LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab, J Clin Oncol, 26, 447, 10.1200/JCO.2007.13.0690
Nyman, 2009, Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP, Mod Pathol, 22, 1094, 10.1038/modpathol.2009.73
Meyer, 2011, Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab, J Clin Oncol, 29, 200, 10.1200/JCO.2010.30.0368
Visco, 2012, Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, Leukemia, 26, 2103, 10.1038/leu.2012.83
Coutinho, 2013, Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies, Clin Cancer Res, 19, 6686, 10.1158/1078-0432.CCR-13-1482
Culpin, 2013, Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients, Histopathology, 63, 788, 10.1111/his.12223
Went, 2009, CD5 expression in de novo diffuse large B-cell lymphomas, Ann Oncol, 20, 789, 10.1093/annonc/mdn793
Jain, 2013, Recent advances in de novo CD5+ diffuse large B cell lymphoma, Am J Hematol, 88, 798, 10.1002/ajh.23467
Yamaguchi, 2008, De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients, Haematologica, 93, 1195, 10.3324/haematol.12810
Aki, 2004, T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma, Leuk Res, 28, 229, 10.1016/S0145-2126(03)00253-4
El Weshi, 2007, T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature, Leuk Lymphoma, 48, 1764, 10.1080/10428190701559124
Tousseyn, 2011, T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification, Virchows Arch, 459, 557, 10.1007/s00428-011-1165-z
Hartmann, 2013, Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma: endpoints of a spectrum of one disease?, PLoS One, 8, 10.1371/journal.pone.0078812
Gibson, 2009, Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype, Hum Pathol, 40, 653, 10.1016/j.humpath.2008.10.007
Hoeller, 2010, Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations, Hum Pathol, 41, 352, 10.1016/j.humpath.2009.07.024
Adam, 2011, Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly, Adv Anat Pathol, 18, 349, 10.1097/PAP.0b013e318229bf08
Ok, 2014, Prevalence and clinical implications of Epstein-Barr Virus infection in de novo diffuse large B-cell lymphoma in Western countries, Clin Cancer Res, 20, 2338, 10.1158/1078-0432.CCR-13-3157
Wong, 2009, Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly, Leuk Lymphoma, 50, 335, 10.1080/10428190902725813
Leoncini, 2008, Burkitt lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 262
Harris, 2013, Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications, Mod Pathol, 26, S57, 10.1038/modpathol.2012.182
Rosenwald, 2003, Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma, J Exp Med, 198, 851, 10.1084/jem.20031074
Savage, 2003, The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma, Blood, 102, 3871, 10.1182/blood-2003-06-1841
Zamò, 2005, Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas, Mod Pathol, 18, 1448, 10.1038/modpathol.3800440
Hoeller, 2010, BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma, Histopathology, 56, 217, 10.1111/j.1365-2559.2009.03462.x
Orwat, 2012, Intravascular large B-cell lymphoma, Arch Pathol Lab Med, 136, 333, 10.5858/arpa.2010-0747-RS
Ponzoni, 2007, Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting, J Clin Oncol, 25, 3168, 10.1200/JCO.2006.08.2313
Boroumand, 2012, Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammation?, Am J Surg Pathol, 36, 1074, 10.1097/PAS.0b013e3182515fb5
Loong, 2010, Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios, Mod Pathol, 23, 493, 10.1038/modpathol.2009.168
Chan, 2008, DLBCL associated with chronic inflammation, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 245
Pittaluga, 2008, Lymphomatoid granulomatosis, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 247
Delsol, 2008, ALK-positive large B cell lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 254
Laurent, 2009, Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis, J Clin Oncol, 27, 4211, 10.1200/JCO.2008.21.5020
Morgan, 2012, Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma, Adv Hematol, 2012, 529572, 10.1155/2012/529572
Montes-Moreno, 2012, Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge, Leuk Lymphoma, 53, 185, 10.3109/10428194.2011.608447
Wass, 2014, Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response, Eur J Haematol, 92, 268, 10.1111/ejh.12240
Hsi, 2011, Plasmablastic lymphoma and related disorders, Am J Clin Pathol, 136, 183, 10.1309/AJCPV1I2QWKZKNJH
Stein, 2008, Plasmablastic lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 256
Carbone, 2014], KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies, Int J Cancer, 10.1002/ijc.28923
Isaacson, 2008, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 214
Castillo, 2012, Prognosis in primary effusion lymphoma is associated with the number of body cavities involved, Leuk Lymphoma, 53, 2378, 10.3109/10428194.2012.694075
Kobayashi, 2007, Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature, Acta Haematol, 117, 132, 10.1159/000097460
Said, 2008, Primary effusion lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 260
Xiao, 2013, Kaposi sarcoma herpesvirus/human herpesvirus-8-negative effusion-based lymphoma: report of 3 cases and review of the literature, Cancer Cytopathol, 121, 661, 10.1002/cncy.21311
Naresh, 2011, Diagnosis of Burkitt lymphoma using an algorithmic approach applicable in both resource-poor and resource-rich countries, Br J Haematol, 154, 770, 10.1111/j.1365-2141.2011.08771.x
Li, 2013, MYC/BCL2 double-hit high-grade B-cell lymphoma, Adv Anat Pathol, 20, 315, 10.1097/PAP.0b013e3182a289f2
Odqvist, 2014, NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma, Mod Pathol, 27, 1331, 10.1038/modpathol.2014.34
Niitsu, 2009, Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations, Leukemia, 23, 777, 10.1038/leu.2008.344
Li, 2012, B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome, Mod Pathol, 25, 145, 10.1038/modpathol.2011.147
Lin, 2013, The impact of MYC rearrangements and “double hit” abnormalities in diffuse large B-cell lymphoma, Curr Hematol Malig Rep, 8, 243, 10.1007/s11899-013-0169-y
Jaffe, 2008, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 267
Kennedy, 2002, Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review, Br J Haematol, 119, 412, 10.1046/j.1365-2141.2002.03843.x
Chu, 2002, Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study, Leuk Lymphoma, 43, 2335, 10.1080/1042819021000040044
Li, 2012, CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution, J Transl Med, 10, 10.1186/1479-5876-10-84
Miyazaki, 2011, CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab, Ann Oncol, 22, 1601, 10.1093/annonc/mdq627